Chronic Diseases

By Marvin Stein; Andrew Baum | Go to book overview

marker status over time can then be correlated with development of dementia. For example, it may be found that subjects who develop dementia will have had a combination of greater-than-average rate of progression of VBR as well as a 4-point worsening of ADAS score with scopolamine challenge. Or, more simply, those who develop dementia might be found to have a yearly 2-second worsening in trailmaking ability. For practical reasons, some studies, such as scopolamine challenge and CSF neuropeptide determination, will be difficult to obtain longitudinally in large numbers of subjects. Other markers, such as neurocognitive testing, can readily be followed longitudinally if an appropriate cohort can be recruited.

If a marker or combination of markers can be found that can predict development of dementia in a high-risk group, these would need to be studied in the elderly population in general to determine specificity for AD and possible utility as a general screening test. As presented here, the most robust or interesting markers for study include scopolamine sensitivity, cognitive measures including delayed recall and trailmaking, hypercortisolemia or dexamethasone resistance, rate of change of VBR, olfactory acuity, and immune factors including neural antibodies and ACT levels. These potential markers should be studied longitudinally in groups of first degree relatives of well-characterized AD patients, in multicenter trials.


ACKNOWLEDGMENT

Preparation of this manuscript was supported by NIH grants AG-02219 and AG-05138.


REFERENCES

Abraham C. R., Selkoe D. J., & Potter H. ( 1988). "Immunochemical identification of the serine protease inhibitor alpha 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease". Cell, 52, 487-501.

Altstiel L. D., Lawlor B. A., & Johannessen D. J. "Serum levels of acute phase reactants are elevated in patients with Alzheimer's disease and first degree relatives". (Unpublished data).

Altstiel L. D., & Sperber K. ( 1991). "Cytokines in Alzheimer's disease". Progress in Neuropsycho- pharmacology and Biological Psychiatry, 15, 481-495.

Amaducci L. A., Fratiglioni L., Rocca W. A., Fieschi C., Livrea P., Pedone D., Bracco L., Lippi A., Gandolfo C., & Bino G. ( 1986). "Risk factors for clinically diagnosed Alzheimer's disease: A case control study of an Italian population". Neurology, 36, 922-931.

The APA Task Force on Laboratory Tests in Psychiatry. ( 1987). "The Dexamethasone Suppression Test: An overview of its current status in psychiatry". American Journal of Psychiatry, 144, 1253- 1262.

Averbach P. ( 1983). "Two new lesions in Alzheimer's disease (letter)". Lancet, 2, 1203.

-36-

Notes for this page

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
One moment ...
Default project is now your active project.
Project items

Items saved from this book

This book has been saved
Highlights (0)
Some of your highlights are legacy items.

Highlights saved before July 30, 2012 will not be displayed on their respective source pages.

You can easily re-create the highlights by opening the book page or article, selecting the text, and clicking “Highlight.”

Citations (0)
Some of your citations are legacy items.

Any citation created before July 30, 2012 will labeled as a “Cited page.” New citations will be saved as cited passages, pages or articles.

We also added the ability to view new citations from your projects or the book or article where you created them.

Notes (0)
Bookmarks (0)

You have no saved items from this book

Project items include:
  • Saved book/article
  • Highlights
  • Quotes/citations
  • Notes
  • Bookmarks
Notes
Cite this page

Cited page

Style
Citations are available only to our active members.
Buy instant access to cite pages or passages in MLA, APA and Chicago citation styles.

(Einhorn, 1992, p. 25)

(Einhorn 25)

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited page

Bookmark this page
Chronic Diseases
Table of contents

Table of contents

Settings

Settings

Typeface
Text size Smaller Larger Reset View mode
Search within

Search within this book

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

Help
Full screen
/ 344

matching results for page

    Questia reader help

    How to highlight and cite specific passages

    1. Click or tap the first word you want to select.
    2. Click or tap the last word you want to select, and you’ll see everything in between get selected.
    3. You’ll then get a menu of options like creating a highlight or a citation from that passage of text.

    OK, got it!

    Cited passage

    Style
    Citations are available only to our active members.
    Buy instant access to cite pages or passages in MLA, APA and Chicago citation styles.

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn, 1992, p. 25).

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn 25)

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences."1

    1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

    Cited passage

    Thanks for trying Questia!

    Please continue trying out our research tools, but please note, full functionality is available only to our active members.

    Your work will be lost once you leave this Web page.

    Buy instant access to save your work.

    Already a member? Log in now.

    Oops!

    An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.